ClinicalTrials.gg
CompletedNCT03252340Updated Feb 15, 2023

Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

An observational study in Atopic Dermatitis, sponsored by EHL Bio Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-02-15.

Sponsored by EHL Bio Co., Ltd. · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
11
Ages
19 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Dermatitis, Atopic with a site in Korea, Republic of — 7 open to participants now, 18 under way, 7 of them phase 3. Dermatitis, Atopic · Korea, Republic of.

Enrollment
12th of 12
11 · median 101
Started
2017
with 2 others
Observational
12 of 83
3 open now
Registered
22nd of 83
by date
Lead sponsor
4 of 83
EHL Bio Co., Ltd.

Among the 83 studies in Dermatitis, Atopic with a site in Korea, Republic of, this one is the 12th largest by enrollment of the 12 observational ones that give a count, is one of 3 that started in 2017, is one of 12 observational ones, and was the 22nd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

7 of the 83 studies in Dermatitis, Atopic with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 19 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Dermatitis, Atopic with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study aims to evaluate safety in subjects with over moderately subacute and chronic atopic dermatitis after an intravenous injection of ADSTEM Inj. Since this is an observational study of patients participated in Phase 1 clinical trials, no drug is administered in this study.

Read the detailed description

Participants will be followed-up for adverse events on each visit. Visits will be on 6, 12, 18, 24, 30, 36, 48, 60months after treatment of ADSTEM Inj.

Time perspective is both retrospective and prospective.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who participated in Phase I clinical trials

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who participated in Phase I clinical trials
  • Patients who voluntarily agreed to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Patients who can not follow-up from the end of the phase 1 clinical trial to the end of the study
05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
11 participants (actual)
Patient registry
No

Groups and cohorts

  • Drug: ADSTEM Inj.

    Participants in Phase I clinical trials treated with ADSTEM Inj.

    Drug: ADSTEM Inj.

Interventions

  • DrugADSTEM Inj.

    1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial. 2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.

06

What researchers measure

Primary outcomes

  1. Tumor formation

    The number of subjects with treatment-related tumor formation

    Time frame: 60months after treatment of ADSTEM Inj.

Secondary outcomes

  1. Adverse events

    The number of subjects with treatment-related adverse events

    Time frame: 60months after treatment of ADSTEM Inj.

07

Study locations

1 site
  • Chungnam National University Hospital
    Daejeon, Chungcheongnam-do, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Aug 2022, 58 months.

Of 74 industry-sponsored observational studies under Dermatitis, Atopic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 84. This study's 58 months is above that.

Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2017
First posted
Aug 17, 2017
StartActual
Sep 19, 2017
Primary completionActual
Aug 17, 2022
CompletionActual
Sep 27, 2022
Last update
Feb 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03252340
Lead sponsor
EHL Bio Co., Ltd.
Responsible party
Sponsor
First posted
Aug 17, 2017
Start date
Sep 19, 2017
Primary completion
Aug 17, 2022
Completion
Sep 27, 2022
Last update
Feb 15, 2023

Study contacts

Young-joon Seo, M.D, Ph.D
principal investigator · Chungnam National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion